Tokenized Private Assets: Synthetic vs Backed Claims

Two products can carry the same ticker-style name, trade on the same screen and move on the same blockchain, yet hand the holder entirely different rights. One is a legal claim on a private asset held in a regulated structure. The other is a derivative that pays out against a price reference and gives the holder no claim on anything. As private-market exposure moves onchain, that difference is the first question an allocator should ask, not the last. This piece offers a five-test checklist for sorting tokenized private assets into backed claims and synthetic exposure.

The Distinction That Prices Everything

A backed token represents an economic interest that exists in law: shares, LLC units, a note, or a beneficial interest in a special purpose vehicle that owns the asset. The token is the record of that interest. If the platform disappeared tomorrow, the holder would still have a claim that a court could recognize.

A synthetic product represents a contract. The issuer promises to pay an amount linked to a reference, such as the valuation of a private company, a commodity price or a property index. The holder owns a counterparty promise, and the value of that promise depends on the issuer's balance sheet, the contract terms and the integrity of the price source.

Neither is inherently illegitimate. Synthetic exposure can be useful for hedging and for reaching assets that cannot be transferred. The problem is labeling. When a synthetic is marketed with the vocabulary of ownership, buyers price it as if it were backed, and the gap shows up only under stress. Our pillar on proof of reserve covers how reserves are verified; this piece covers what the reserves are supposed to be backing in the first place.

A Five-Test Checklist

Score any tokenized private asset against these tests. A "no" on the first is disqualifying for anything described as ownership.

1. Legal claim on the asset. Can the issuer point to the instrument that gives the holder a direct or beneficial interest? Look for the issuing entity, the governing documents and the chain from token to asset. If the answer is "a total return swap with the issuer," the product is synthetic.

2. Custody and reserve attestation. Who holds the underlying shares, units or title, and who attests to it? A backed product should be able to publish periodic, independently sourced evidence that the reserve matches the supply of tokens. Without it, "backed" is an assertion. Machine-readable attestations, such as Chainlink Proof of Reserve feeds, make that check continuous rather than annual.

3. Transfer restrictions. Private securities are restricted by design. Securities sold under Regulation D are generally restricted securities, and resale typically runs through the holding-period conditions of Rule 144. Offshore issuance under Regulation S carries its own distribution compliance period under Rule 903. A token that trades freely 24 hours a day while the underlying share is locked is either synthetic or mislabeled.

4. Investor eligibility. Who may hold it, and is that enforced at the wallet level or only in a terms-of-use page? Accredited-investor status, jurisdiction checks and whitelisting should be enforced by the token's transfer logic. Eligibility that exists only in marketing copy is not eligibility.

5. Dispute venue. If the issuer, the custodian or the platform fails to perform, where does the holder go? A named court, arbitration forum and governing law belong in the offering documents. Synthetic products issued offshore through thin entities often leave this blank.

Scoring a Synthetic Pre-IPO Product Against a Backed Issuance

Pre-IPO exposure is where the distinction is easiest to see, because demand is high and the underlying shares are the hardest to move.

Take a synthetic product referencing a private company's valuation. On test one it fails: the holder has a contract, not a share. On test two it depends on whether the issuer actually holds hedging shares, and if so, whether that is disclosed. On test three the underlying is locked up by the company's own transfer rules, so the token's liquidity is the issuer's, not the asset's. Tests four and five depend entirely on the platform.

Now take a Regulation D backed issuance: an SPV holds the shares, investors hold units in the SPV, the units are recorded on a ledger with transfer restrictions coded in, eligibility is verified before wallet approval, and the offering documents name a venue. It scores well on all five, and it is correspondingly less liquid, because it inherits the restrictions of what it holds.

That trade-off is the honest summary. Backed claims give up some liquidity to preserve rights. Synthetics preserve liquidity by giving up rights. Allocators can choose either, but only if the product tells them which one they are buying.

The Question the Listing Day Raises

The hardest unanswered question for synthetic pre-IPO products is what happens when the referenced company lists. Several things have to be settled in advance, and many products do not say:

• Who is the settlement party for open contracts, and is their obligation capped by the collateral they hold?
• Which price source governs the final settlement: the opening auction, the first trade, a volume-weighted average or a committee determination?
• What happens in the gap between the last private mark and the first public price, when the two can differ by a wide margin?
• Is there a halt, a netting window or a redemption period, and who decides?

A backed claim answers these by construction. When the company lists, the SPV's shares become eligible for resale once restrictions lapse, and unit holders receive their pro rata interest or proceeds under terms fixed at issuance. A synthetic answers them by contract, and the contract is only as good as its drafting and its issuer.

What Institutions Should Ask For

Treat the checklist as a standard data request. Before allocating, ask for the governing documents, the custody agreement, the latest attestation and its source, the transfer-restriction logic and the dispute clause. Ask whether the token's own smart contract enforces the restrictions or whether they are off-chain policy. Ask what the product does at a corporate event, such as a listing, merger or default.

Platforms that can answer in a single data room are signaling that the structure was designed for institutional review. Platforms that answer with marketing pages are telling you the same thing. For a view of how issuance, settlement and records fit together end to end, see how it works, and browse structured offerings on the marketplace with these five tests in hand.

Where This Is Heading

As more private exposure moves onchain, the market will likely converge on standard disclosure: a plain label for backed versus synthetic, a published reserve attestation, and machine-readable eligibility rules. Institutions that adopt the checklist now will be ahead of that convergence, and issuers who build to it will find that clarity widens their buyer base rather than narrowing it. The point of putting private assets onchain is better access, faster settlement and more transparent data. Those benefits only compound when the token and the asset are demonstrably the same thing.

Prefer email? Send the offering memo or a short asset summary to deals@commertize.com. We reply within one business day, with no obligation to engage us.